Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation
Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation

NCT04872621

CompletedN/A

Sponsor: AstraZeneca

Conditions: Relapsed or Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Lymphoma)

Countries: Japan

To understand the incidence of ADRs of Calquence 100 mg capsules (acalabrutinib) used in patients with relapsed or refractory chronic lymphocytic leukaemia (including small lymphocytic lymphoma) in a real-world post-marketing setting

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

Patients with relapsed or refractory chronic lymphocytic leukemia (small lymphocytic lymphoma) who are treated with the product -

Exclusion Criteria:

None

\-
Locations (59)
  • Aichi, Japan
  • Aichi, Japan
  • Akita, Japan
  • Aomori, Japan
  • Chiba, Japan
  • Chiba, Japan
  • Fukui, Japan
  • Fukuoka, Japan
  • Fukuoka, Japan
  • Gifu, Japan
  • Gunma, Japan
  • Gunma, Japan
  • Hiroshima, Japan
  • Hiroshima, Japan
  • Hokkaido, Japan
  • Hokkaido, Japan
  • Hyōgo, Japan
  • Hyōgo, Japan
  • Ibaraki, Japan
  • Ibaraki, Japan
  • Ishikawa, Japan
  • Kagoshima, Japan
  • Kagoshima, Japan
  • Kanagawa, Japan
  • Kanagawa, Japan
  • Kochi, Japan
  • Kumamoto, Japan
  • Kyoto, Japan
  • Kyoto, Japan
  • Mie, Japan
  • + 29 more on CT.gov